$14.160
-0.538 (-3.80%)收盘时
CRVS 资讯
CRVS 事件
Corvus Highlights Soquelitinib's Potential in Immune Disease Treatment
"We started the year with strong momentum for soquelitinib, our selective ITK inhibitor that we believe is well positioned to improve therapy for a broad range of patients with atopic dermatitis, other immune diseases and cancers," said Richard A. Miller, co-founder, president and chief executive officer of Corvus. "The data generated from our clinical and preclinical work support soquelitinib's potential to provide a new treatment paradigm for these diseases based on a rebalancing of the immune system. We will share additional data supporting this mechanism at the upcoming annual meeting of the Society for Investigative Dermatology, where we are reviewing data from our Phase 1 atopic dermatitis trial in two oral presentations. Looking forward, we are focused on our ongoing and planned soquelitinib clinical trials, including the initiation of new Phase 2 studies in hidradenitis suppurativa and asthma anticipated later this year."
Corvus Pharmaceuticals Files Automatic Mixed Securities Shelf
Corvus Pharmaceuticals files automatic mixed securities shelf
Corvus Claims Soquelitinib Could Be Important New Medicine
"We believe the recent cohort 4 data from our Phase 1 atopic dermatitis trial demonstrate that soquelitinib has the potential to be an important new medicine for a broad range of patients with atopic dermatitis and other immune diseases," said Richard A. Miller, co-founder, president and chief executive officer of Corvus. "The data also highlight the unique mechanism of action with ITK inhibition, regulating multiple T cell functional pathways that leads to an immune system resetting that may be effective in treating many diseases. Our near-term focus is the ongoing enrollment of our registration Phase 3 peripheral T cell lymphoma trial, getting off to a strong start with our recently initiated Phase 2 atopic dermatitis trial, and reporting additional data from the Phase 1 trial at the Society of Investigative Dermatology meeting. We are also advancing our plans to initiate two additional Phase 2 trials in asthma and hidradenitis suppurativa later this year. Our recent financing will enable us to advance all of these programs through key data readouts, providing significant opportunity to further demonstrate the value of soquelitinib's pipeline-in-a-product potential."
Jefferies and Goldman Sachs Increase Deal Size to $175M
The deal size was increased to $175M in common stock from $150M in common stock. Jefferies and Goldman Sachs acted as joint book running managers for the offering.
Trump Proposes Tariffs on European Goods, Markets Rattle
The return from long weekend saw the markets getting rattled as President Trump's proposed tariffs starting at 10% on goods from several European countries related to disputed control of Greenland enflamed cross-Atlantic tensions. Higher-beta names led the declines as investors rotated out of risk-assets in the U.S. - Tech, Consumer Discretionary, and Financials were the worst performers on the S&P 500 while Consumer Staples was the single sector in the green. Precious metals, meanwhile, continued their move higher amid the risk-off environment, with an added boost coming as a result of lower U.S. Dollar. Longer-term Treasury yields also rose as investors fret that European holders will be inclined to cut their U.S. debt positions - Tuesday morning headline that Danish Pension Fund Akademiker sold its U.S. Treasuries was greeted with increasing unease by the U.S. fixed income markets.Following the broad-based selling, the opening hour of the evening session is seeing some modest relief - S&P e-minis, Dow Industrials, and Nasdaq 100 contracts are all up by a decimal, though sentiment may yet turn sour as disappointing guidance accompanying earnings out of Netflixis pressuring the stock afterhours and signaling consumer caution even with one of the internet "staples" in the Communication Services. In commodities, WTI Crude Oil is back below $60 per barrel mark, though Gold and Silver remain buoyed around $4,780 and $95 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Progress Softwareup 7.1%United Airlinesup 3.4%Zions Bancorporationup 1.8%DOWN AFTER EARNINGS -Netflixdown 4.8%Bank OZKdown 3.7%Hancock Whitneydown 1.3%Interactive Brokersdown 0.8%ALSO LOWER -Newegg Commercedown 11.4% after disclosing Chairman detainmentCorvus Pharmaceuticalsdown 7.4% after equity offeringBioAge Labsdown 3.6% after equity offering
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。